Canada: New Canadian Patent Office Practice Notice Regarding Medical Uses


On June 10, 2013, the Canadian Intellectual Property Office ("CIPO") issued Practice Notice PN 2013-04 (the "Notice"), which provides guidelines to be followed in the examination of patent claims covering medical uses.

In Canada, methods of medical treatment are considered to fall outside the scope of the definition of "invention" provided by the Patent Act. Claims directed to such methods are, therefore, considered to be directed to non-patentable subject matter, and rejected as invalid during prosecution. However, certain forms of medical "use" claims, such as those directed to "use of [compound] for treatment", "use of [compound] in the manufacture of a medicament for treatment" or "[compound] for use in treatment", are generally considered to be valid, so long as no active treatment or surgical steps are recited. The Notice is intended to provide examiners specific guidance with respect to the examination of such "medical use" type claims.

As an introductory point, the Notice states that, although medical use claims will generally be allowed, when it is determined that such claims "prevent physicians from exercising their skill and judgment in using a known compound for an established purpose", they will be considered to effectively cover a method of medical treatment, and should be rejected by the examiner. The Notice then goes on to provide guidance as to how examiners should evaluate claims in making such a determination.

Purposive Claim Construction

With reference to the 2011 Federal Court of Appeal decision in Canada (Attorney General) v. ("Amazon"), and to the recently issued Practice Notice PN 2013-02, the current Notice states that any patentable subject matter determination must be based on a purposive construction of the claim in issue. In this respect, the Notice may be considered a departure from past CIPO practice regarding patentable subject matter, which practice had relied on an assessment of the nature of the "contribution" of the claim.

The Canadian approach to purposive construction was established by the Supreme Court of Canada's leading decision in Free World Trust v. Électro Santé Inc.In that decision, the Court stated that:

The claims language will, on a purposive construction, show that some elements of the claimed invention are essential while others are non-essential. The identification of elements as essential or non-essential is made:

i.on the basis of the common knowledge of the worker skilled in the art to which the patent relates; of the date the patent is published;

iii.having regard to whether or not it was obvious to the skilled reader at the time the patent was published that a variant of a particular element would not make a difference to the way in which the invention works; or

iv.according to the intent of the inventor, expressed or inferred from the claims, that a particular element is essential irrespective of its practical effect;

v.without, however, resort to extrinsic evidence of the inventor's intention.

By comparison, the purposive construction analysis set out in the Notice emphasizes the identification of the "problem the inventors set out to address and the solution disclosed". In carrying out this analysis, the Notice instructs the examiner to consider what the inventors state about the background of the invention, their objectives, and specific problems, needs, limitations or advantages known in the art. The Notice states that the identification of the problem should be guided by the examiner's understanding of the common general knowledge and the description itself.   

Patentability Determined Based on Nature of "Essential Elements"

After having identified the problem and solution, the Notice instructs the examiner to then determine which claim elements are "essential" and "non-essential" to the solution. If any of the so-identified "essential elements" is considered to instruct a medical professional "how" to treat a patient, that claim should be considered as being directed to a method of medical treatment, and therefore rejected by the examiner as invalid. By contrast, claim elements directed to "what" to use to treat the patient should not result in a finding of invalidity.

By way of example, the Notice lists several claim elements of particular interest to patent applicants interested in the rapidly developing field of personalized medicine, namely: dosing schedules; dosage ranges; limitations of treatment to a patient sub-population; and sites of administration, as "how" elements that, if deemed "essential" to a claim, should result in that claim's rejection.  

Accordingly, the impact of the Notice on the patentability of medical use claims that recite limitations according to dosage, patient sub-population, and site of administration, is likely to depend on whether examiners construe such limitations as being directed to a "what" or a "how". 

The Notice also states that in cases where "how" elements, including dosage schedules or dosage regimens, are deemed to be non-essential, their "mere recitation" in a claim "does not necessarily mean the claim is non-statutory".

Although not specifically addressed by the Notice, use claims directed to a series of specific dosages would appear to be allowable, as such claims arguably recite limitations directed to a number of vendible products (a "what" rather than a "how"). Given that there are no additional claim fees in Canada, one appropriate response to the Notice may be to dissect such dosage range claims, thereby claiming uses of a series of discrete dosages.

With respect to claim limitations to a patient sub-population or site of administration, the Notice does not specifically address how such limitations, if worded in passive form (eg. "for administration to a site"), should be construed.  It is possible that such limitations, if appropriately worded, may be construed as directing the "what", rather than the "how", and may thus be allowable in view of the Notice. 


The Notice represents the latest of several steps taken by CIPO in its ongoing attempt to clarify Canadian Patent Office practice where the patentability of claimed subject matter relating to medical uses is at issue. This guidance started with the re-working of section 13.05.03 of the Manual of Patent Office Practice in 2009, which was effectively rescinded in part by Practice Notice PN2011-04, published in 2011, which in turn has been explicitly rescinded by the March 18, 2013 "Practice Guidance Following the Amazon FCA Decision".

Whether the Notice is successful in this regard will likely depend upon how it is ultimately applied by examiners. In this respect, it may be appropriate to consider the following passage from the Federal Court of Appeal's decision in Amazon:

Anyone who undertakes a purposive construction of a patent must do so on the basis of a foundation of knowledge about the relevant art, and in particular about the state of the relevant art at the relevant time. For the Commissioner [represented during patent prosecution by the examiner], that assistance comes in the form of submissions from the patent applicant and, I assume, from staff at the patent office with the appropriate experience. [Emphasis added.]

In this spirit, if CIPO encourages examiners to solicit and consider the assistance of patent applicants during prosecution with respect to, among other things, the critical step of purposive construction, the Notice may well achieve its stated goal of ensuring "efficient, predictable and reproducible examination" of medical use claims.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
8 Nov 2016, Seminar, Ottawa, Canada

The prospect of an internal investigation raises many thorny issues. This presentation will canvass some of the potential triggering events, and discuss how to structure an investigation, retain forensic assistance and manage the inevitable ethical issues that will arise.

22 Nov 2016, Seminar, Ottawa, Canada

From the boardroom to the shop floor, effective organizations recognize the value of having a diverse workplace. This presentation will explore effective strategies to promote diversity, defeat bias and encourage a broader community outlook.

7 Dec 2016, Seminar, Ottawa, Canada

Staying local but going global presents its challenges. Gowling WLG lawyers offer an international roundtable on doing business in the U.K., France, Germany, China and Russia. This three-hour session will videoconference in lawyers from around the world to discuss business and intellectual property hurdles.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.